No Data
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability
Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $20 From $22
Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Express News | Adverum Biotechnologies Inc : Truist Securities Cuts Target Price to $40 From $60
QMengColdJoke : I am buying back, this designation itself means nothing but in the end will make final approval easier and faster.